Patents by Inventor Mayuka Horikawa

Mayuka Horikawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions combining immunotherapy with monocyte activation
    Patent number: 9814740
    Abstract: Methods of enhancing the effectiveness of an antibody-based therapeutic agent are provided herein. The methods include administering an antibody-based therapeutic and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells to a subject in need of such treatment. The subject may have cancer, an autoimmune disease, an infectious disease or an immunodeficiency. The composition capable of preferentially activating monocytes or macrophages may be a TLR3 agonist. The composition capable of preferentially depleting B10 cells may be a CD19 antibody. Pharmaceutical compositions comprising an antibody-based therapeutic agent and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells are also provided.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: November 14, 2017
    Assignee: Duke University
    Inventors: Thomas Tedder, Mayuka Horikawa
  • METHODS AND COMPOSITIONS COMBINING IMMUNOTHERAPY WITH MONOCYTE ACTIVATION
    Publication number: 20130309244
    Abstract: Methods of enhancing the effectiveness of an antibody-based therapeutic agent are provided herein. The methods include administering an antibody-based therapeutic and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells to a subject in need of such treatment. The subject may have cancer, an autoimmune disease, an infectious disease or an immunodeficiency. The composition capable of preferentially activating monocytes or macrophages may be a TLR3 agonist. The composition capable of preferentially depleting B10 cells may be a CD19 antibody. Pharmaceutical compositions comprising an antibody-based therapeutic agent and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells are also provided.
    Type: Application
    Filed: December 21, 2011
    Publication date: November 21, 2013
    Applicant: DUKE UNIVERSITY
    Inventors: Thomas Tedder, Mayuka Horikawa